RecruitingNCT06781359

Study on Plasmablastic Lymphoma Patients

An International Multicenter Observational Retrospective Study on Plasmablastic Lymphoma Patients

Sponsor

Fondazione Italiana Linfomi - ETS

Enrollment

200 participants

Start Date

Feb 14, 2025

Study Type

OBSERVATIONAL

Conditions

Plasmablastic Lymphoma

Summary

This is an observational, multicenter, international and retrospective study, that aims to collect data on clinical and pathological characteristics, treatment regimens, outcome, and prognostic factors (clinical, biomarkers and/or radio-metabolic) in patients affected by PBL.

Eligibility

Min Age: 15 Years

Inclusion Criteria5

Diagnosis of plasmablastic lymphoma (PBL) between Jan 1st 2000, and Dec 31st 2022
Histologically confirmed plasmablastic lymphoma (PBL) diagnosis according to local pathological report
Age \> 18 years old
Availability of complete medical records
Availability of histopathological material requested by the study

Exclusion Criteria3

Any other histology than PBL
Lack of complete medical records
Lack of histopathological material requested by the study

Locations(23)

IRCCS Centro di Riferimento Oncologico di Aviano, Divisione di Oncologia e dei Tumori immuno-correlati

Aviano, PN, Italy

Ospedale C.e G. Mazzoni, U.O.C. di Ematologia

Ascoli Piceno, Italy

ASST Spedali Civili di Brescia, Ematologia

Brescia, Italy

A.O. S. Croce e Carle, S.C. di Ematologia e Trapianto di Midollo Osseo

Cuneo, Italy

Azienda Ospedaliera Universitaria Careggi, Unità funzionale di Ematologia

Florence, Italy

ASST -Fatebenefratelli - Polo Luigi Sacco Oncologia

Milan, Italy

ASST Grande Ospedale Metropolitano Niguarda, SC Ematologia

Milan, Italy

Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia

Milan, Italy

Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda, Ematologia

Milan, Italy

Fondazione IRCCS San Gerardo dei Tintori, Ematologia

Monza, Italy

AOU Maggiore della Caritа di Novara, SCDU Ematologia

Novara, Italy

Azienda Ospedaliera Universitaria di Padova, Ematologia

Padua, Italy

Presidio ospedaliero A. Tortora, U.O. Onco-ematologia

Pagani, Italy

Azienda Unitа Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova, Ematologia

Reggio Emilia, Italy

Azienda Ospedaliera Universitaria Sant' Andrea, Ematologia

Roma, Italy

Policlinico Umberto I - Università La Sapienza, Istituto Ematologia, Dipartimento di Medicina Traslazionale e di Precisione

Roma, Italy

Universitа Cattolica S. Cuore, Ematologia

Roma, Italy

Azienda Ospedaliero Universitaria Senese, U.O.C. Ematologia

Siena, Italy

A.O.U. Città della Salute e della Scienza di Torino, Ematologia Universitaria

Torino, Italy

A.O.U. Città della Salute e della Scienza di Torino, S.C. Ematologia

Torino, Italy

Ospedale S. Chiara, S.S. di Ematologia

Trento, Italy

ULSS2 Marca Trevigiana, Ospedale Ca' Foncello, S.C di Ematologia

Treviso, Italy

ULSS 8 Berica - Ospedale S. Bortolo, Ematologia

Vicenza, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06781359

Related Trials

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

NCT053894231 location

Study of SGR-1505 in Mature B-Cell Neoplasms

NCT0554401936 locations

Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

NCT0491524818 locations

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

NCT056635028 locations

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

NCT041393048 locations